Journal
AAPS PHARMSCITECH
Volume 15, Issue 1, Pages 121-130Publisher
SPRINGER
DOI: 10.1208/s12249-013-0044-0
Keywords
aprepitant; bioavailability; dissolution rate; inclusion complex; sulfobutyl ether-beta-cyclodextrin
Categories
Ask authors/readers for more resources
Aprepitant(APR), a neurokinin 1 receptor antagonist, is an approved treatment for chemotherapy-induced nausea and vomiting and for post-operative nausea and vomiting. However, it has poor water solubility. This study was performed to optimize the capsule formulation of an inclusion complex of APR with sulfobutyl ether-beta-cyclodextrin(SBE-beta-CD), and to evaluate its water solubility, dissolution rate, and bioavailability. The complex was prepared through the saturated-aqueous solution method and then characterized by Fourier transform infrared spectroscopy, x-ray powder diffraction, and differential scanning calorimetry. Subsequently, a pharmacokinetic study was performed using liquid chromatography-tandem mass spectrometry. Emend, which features an innovative formulation that incorporates drug nanoparticles with high bioavailability, was used as a reference for comparison with the optimized formulation. As a result, the dissolution rates and extent of release of the test formulation in various media were enhanced relative to those of Emend. The bioavailability of the drug complex was comparable to that of Emend. In summary, the SBE-beta-CD complexation could provide a practical and cost-effective option for enhancing the solubility and bioavailability of APR according to our research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available